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Abstract Hizentra® (20% subcutaneous immunoglobulin [SCIG]) was administered to subjects
with primary immunodeficiency disease in two extension studies in the EU and US to assess
long-term efficacy and tolerability. Subjects (aged 4–69 years) were treated for 148 weeks in
the EU (N = 40; 5405 infusions) and 87 weeks in the US (N = 21; 1735 infusions). Weekly doses
were 116.0 mg/kg (EU) and 193.2 mg/kg (US); IgG levels were 7.97 g/L (EU) and 11.98 g/L (US).
Annualized rates of serious bacterial infections were 0.05 infections/subject/year (EU) and
0.06 infections/subject/year (US). Rates of any infection were 3.33 infections/subject/year
(EU) and 2.38 infections/subject/year (US). The rate of bronchopulmonary infections was higher
in the EU study. No treatment-related serious AEs occurred; no subject discontinued because of
treatment-related AEs. Self-administered Hizentra afforded sustained effective protection from
infections and favorable tolerability during an extended treatment period of up to 3 years.
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162 S. Jolles et al.1. Introduction they had hypoalbuminemia, protein-losing enteropathies, orPrimary immunodeficiency disease (PIDD) is a group of more
than 200 inherited disorders in which patients are predisposed
to recurrent infections, autoimmune disease, and malignancy
[1,2]. Some of the most common forms of PIDD are asso-
ciated with deficient antibody production capacity and in-
clude common variable immunodeficiency disease (CVID)
and X-linked agammaglobulinemia (XLA). The mainstay of
treatment for patients with antibody deficiency is lifelong
treatment with immunoglobulin (Ig) replacement therapy,
which is known to reduce the risk of infections and their
sequelae [3]. Although the administration of IgG via the
intravenous route (IVIG) has been the predominant treat-
ment for the past 25 years, patients are increasingly receiving
treatment via the subcutaneous route (SCIG) for reasons of
fewer systemic side effects, improved adherence,manageable
self-administration, or personal choice [4–7]. SCIG is absorbed
more slowly into the bloodstream and is given more frequently
than IVIG; thus, a less variable steady-state IgG level is main-
tained, which eliminates the peaks and troughs that occur with
monthly IVIG therapy [7]. Maintenance of steady-state Ig levels
may reduce the “wear-off” effects that have been reported
toward the end of an IVIG dosing cycle [3,6,8].
Hizentra® (CSL Behring, King of Prussia, PA), a 20% Ig
replacement product specifically formulated for lower-volume
subcutaneous administration (compared with 10% and 16% Ig
products), was assessed in 2 pivotal clinical trials in the
European Union (N = 51) and in the United States (N = 49)
[9,10]. These trials, which lasted more than 40 weeks and
60 weeks, respectively, demonstrated the safety and efficacy
of Hizentra. Patients with genetic defects resulting in PIDD
usually require Ig replacement therapy throughout their
lifetime; therefore, long-term studies are necessary to establish
that protection from infections can be sustained. In addition,
long-term studies are needed to demonstrate that repeated
self-administration of SCIG, often with multiple infusion
sites, remains acceptable, practical, and well tolerated for
patients over extended periods. Currently, published studies
of Ig products approved for subcutaneous use report efficacy
and safety for up to 15 months only [9–12]. Consequently, the
long-term efficacy, safety, and tolerability of Hizentra were
examined in 2 extension studies that collected data from
subjects who took part in the aforementioned EU and US
pivotal studies, for a treatment duration of up to 3 years
(ClinicalTrials.gov identifiers: NCT00751621 [EU],
NCT00719680 [US]).
2. Subjects and methods
2.1. Subjects
Subjects who had enrolled in the preceding pivotal studies of
Hizentra conducted in the European Union and the United
States [9,10] were offered the opportunity to participate in
the extension studies. Subjects in both extension studies had
either CVID or XLA as defined by the Pan-American Group for
Immunodeficiency and the European Society for Immunode-
ficiency [13]. Subjects with autosomal recessive agamma-
globulinemia (ARAG) were also eligible for the EU extension
study. Subjects in both extension studies were excluded ifproteinuria. The US extension study also excluded subjects
with an ongoing serious bacterial infection (SBI) at the time
of screening.
The extension studies were conducted in accordance with
the International Conference on Harmonisation, Good Clinical
Practice guidelines, and the Declaration of Helsinki (1996
version). Study protocols and informed consent documents
were reviewed and approved by the appropriate institutional
review boards or independent ethics committees. Written
informed consent was obtained for each subject.
2.2. Study design
These were prospective, open-label, single-arm, phase 3
extension studies in the European Union (13 sites, between
August 2008 and December 2011) and the United States (4
sites, between June 2008 and June 2010) in patients with
PIDD who had previously been treated with Hizentra in
pivotal studies [9,10]. Starting doses of Hizentra were the
same as the last dose for each subject in the preceding
pivotal study and could be adjusted if medically indicated or
if a subject's weight changed by more than ±5% at any time
during the study. In addition, doses in the US study could be
adjusted if the trough level fell outside individual limits
carried over from the pivotal study. Subjects in the EU study
were allowed to have their weekly dose distributed over
several days, whereas in the US study, doses were given
once or twice per week according to subject preference and
the clinical judgment of the investigator. Regardless of dosing
frequency, the total weekly dose remained unchanged. The
studies were planned to continue until the product became
commercially available.
The number of injection sites for each subject was deter-
mined by the total volume to be administered. The initial
volume per injection sitewas equal to that administered at the
subject's last infusion during the pivotal study but could be
increased to a maximum of 40 mL/site if preferred by the
subject or recommended by the investigator. The initial
infusion rate was the same as the rate of last administration
of the pivotal studies and could be increased to a maximum
total infusion rate of 35 mL/h in the EU extension study
or 70 mL/h in the US extension study (if using 2 pumps
simultaneously), depending on the subject's tolerability and
investigator recommendation. Training in self-administration
of Hizentra was conducted during the pivotal trial; retraining
could be conducted if necessary.
Premedications such as prophylaxis against infusion reac-
tions on the day of infusion were not permitted. Oral and
parenteral steroids were permitted in the US extension
study if the average daily dose was b0.15 mg of prednisone
equivalent/kg per day.
2.3. Efficacy and safety assessments
The annual rate of SBIs was assessed in both studies (as
defined by the US Food and Drug Administration [FDA]:
bacterial pneumonia, bacteremia/septicemia, osteomyeli-
tis/septic arthritis, bacterial meningitis, visceral abscess
[14]). Additional efficacy outcomes captured from subject
diaries included the number of any infectious episodes
163(“infection” designated at the discretion of the investigators);
the number of days missed from work/school/kindergarten/
day care or unable to perform normal daily activities due to
infections; the number of days of infection-related hospital-
ization; and the number of days of antibiotic usage for infec-
tion prophylaxis and treatment. Total serum and selected
specific IgG levels for bacterial and viral pathogens were
measured prior to infusion at the first visit and then at months
6, 12, 18, 24, 30, 36, and 42 in the EU study, while only total
serum IgG levels were measured in the US study at the first
visit and at weeks 24, 48, 72, 96, and 120 (Table S1).
Safety evaluation included assessment of adverse events
(AEs) and local tolerability. A schedule of safety evaluations
is shown in Table S1. In both extension studies, local toler-
ability was evaluated by subjects, and comments were
recorded in diaries. Injection sites in the US extension study
were assessed by subjects 24 ± 3 h following every Hizentra
administration and reactions were classified as none, very
slight, slight, moderate, or severe. In addition, local reactions
could be reported via standard AE reporting methods at any
time during the study. No specific time point for assessment of
local reactions was designated in the EU extension study;
however, local reactions were identified manually from AE
listings during each study visit. “Local reaction” included, but
was not limited to, infusion-site edema, infusion-site reaction,
injection-site pain, injection-site rash, and injection-site reac-
tion. Systemic AEs were recorded by subjects and observed by
investigators at study visits. Vital signs were evaluated at
screening and before and after each infusion at the study site
during both studies (Table S1). Routine laboratory parameters
were determined pre-infusion at visits 3, 5, 7, 9, 11, 13, and 15
and completion visit of the EU study and at weeks 1, 24, 48, 72,
96, and 120 and the completion visit of the US study (Table S1).Table 1 Demographic and baseline characteristics at
enrollment into the extension study.
Characteristic EU study
(N = 40)
US study
(N = 21)
Gender, n (%)
Female 12 (30.0) 15 (71.4)
Male 28 (70.0) 6 (28.6)
Age (years)
Mean (SD) 21.6 (15.31) 42.4 (18.53)
Median (range) 16.0 (4–52) 42.0 (11–69)
Age group, n (%)
2 to b12 years 15 (37.5) 1 (4.8)
12 to b16 years 4 (10.0) 1 (4.8)
16 to b65 years 21 (52.5) 16 (76.2)
≥65 years 0 3 (14.3)
Race, n (%)
White 40 (100) 21 (100)
Body mass index (kg/m2)
Mean (SD) 20.5 (4.67) 26.4 (6.46)
Median (range) 20.5 (14–31) 26.2 (18–43)
Primary disease, n (%)
CVID 23 (57.5) 21 (100)
XLA 16 (40.0) 0
ARAG 1 (2.5) 0
ARAG = autosomal recessive agammaglobulinemia; CVID = com-
mon variable immunodeficiency; SD = standard deviation;
XLA = X-linked agammaglobulinemia.2.4. Statistical methodology
Sample size for the extension studies was determined by the
number of subjects agreeing to continue from the respective
short-termpivotal studies. Efficacy analysis in the EU extension
study was performed in the all-treated (AT) population (all
subjects treated with Hizentra), and in the US extension study,
efficacy was assessed in the intent-to-treat (ITT; all subjects
treated with Hizentra for whom any efficacy data was
available) and per-protocol efficacy (PPE; all subjects who
completed ≥48 weeks of the efficacy period that started
with the first Hizentra dose in this study) populations. The
results of the PPE analysis were similar to those of the ITT
analysis and are not presented here. Safety assessment was
performed in the AT population in both extension studies.
The annualized rate of SBIs was calculated along with the
upper 1-sided 99% confidence limit (CL) using a chi-square
distribution. No imputation was made for subjects who
discontinued the study. The annualized rate of all infec-
tions was calculated with a 2-sided 95% confidence interval
(CI). Annualized rates and descriptive statistics were
calculated for days missed from school/work/kindergar-
ten/day care, days hospitalized, and days of antibiotic use.
Serum IgG levels were analyzed using descriptive statistics.
Bronchopulmonary AE rates, including the preferred terms
bronchitis, bronchitis acute, bronchitis bacterial, bronchi-
tis chronic, bronchitis pneumococcal, bronchitis viral,influenza, mycoplasma infection, pneumonia, pneumonia
bacterial, productive cough, pulmonary tuberculosis, and
tracheitis, were analyzed and compared between studies
post hoc using a 95% CI for the difference of exposure-adjusted
rates [15]. To assess potential enrollment bias based on
tolerability, rates per infusion were compared post hoc using a
Wilcoxon test between subjects who did and did not enter the
US extension study from the pivotal trial.3. Results
3.1. Subjects
Baseline characteristics for subjects in both extension studies
are presented in Table 1. In the EU extension study, 40 of 43
subjects who completed the pivotal study were screened,
enrolled, and treated with Hizentra. All 40 subjects were
included in the efficacy analysis. Four subjects discontinued
during the study (1 non-treatment-related death, 1 withdrew
consent, 1 moved to another country, and 1 was excluded for
lack of adherence to anti-inflammatory therapy for asthma)
and 36 (90%) completed the study. The mean age of subjects
was 21.6 years and the study included 15 children (37.5%) and
4 adolescents (10.0%). Most subjects (57.5%) had CVID, 40.0%
had XLA, and 1 had ARAG. The median disease duration at
enrollment was 6 years.
In the US extension study, 21 of 28 subjects who completed
the pivotal study were screened, enrolled, and treated with
Hizentra. All 21 subjects were included in the efficacy analy-
sis. In a post hoc analysis to determine enrollment bias, there
was no difference in AE rates between the 7 subjects who
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21 subjects who continued Hizentra treatment in the US
extension study (median, min–max: 0.32, 0.11–0.89 for those
who discontinued and 0.65, 0.08–1.36 for those who contin-
ued; P = 0.4175). Five subjects discontinued during the study
(3 withdrew consent, 1 was lost to follow-up, 1 discontinued
because of thyroid cancer, a non-treatment-related serious AE
[SAE]) and 16 subjects (76.2%) completed the study. Themean
age of subjects was 42.4 years, and the study included 1 child
(4.8%) and 1 adolescent (4.8%). All subjects in the US study had
CVID, with a disease duration of N5 years at the time of
enrollment.3.2. Study drug administrationA total of 5405 infusions were administered in the EU study.
The median of individual median doses was 116.0 mg/kg body
weight. Weekly doses ranged from 54 mg/kg to 406 mg/kg.
The median treatment period was 148 weeks (range, 9–
166 weeks).
A total of 1735 infusions were administered in the US
extension study. All subjects received weekly doses, exceptTable 2 Efficacy outcomes, including infections occurring in ≥1
Endpoint EU study
AT popul
(N = 40)
Number
(%) of
subjects
Serious bacterial infections a
[Upper 99% CL]
5 (12.5)
All infection episodes a
[95% CI]
38 (95.0)
Bronchitis 21 (52.5)
Upper respiratory tract infection 18 (45.0)
Sinusitis 13 (32.5)
Cough 8 (20.0)
Nasopharyngitis 12 (30.0)
Rhinitis 9 (22.5)
Febrile infection 6 (15.0)
Pharyngitis 5 (12.5)
Acute sinusitis 5 (12.5)
Pneumonia bacterial 5 (12.5)
Viral upper respiratory tract infection 4 (10.0)
Influenza 4 (10.0)
Viral infection 4 (10.0)
Days missed from work/school/kindergarten/day
care or unable to perform normal activities due
to infections
27 (67.5)
Days hospitalized due to infections 7 (17.5)
Days with antibiotics for infection prophylaxis or
treatment
36 (90.0)
Serum Ig concentration, mean (SD), g/L 7.97 (1.1
CI = confidence interval; CL = confidence limit.
a The total number of days in the EU study was 38,208 and in the USone subject who received 50 weekly doses divided into
2 infusions/week. The median of individual median weekly
doses was 193.2 mg/kg body weight, and doses ranged from
97 mg/kg to 354 mg/kg per week. The median total infusion
rate was 50 mL/h (range, 15–70 mL/h). The median treat-
ment period was 87 weeks (range, 11–104 weeks).3.3. Efficacy
3.3.1. EU extension study
There were 5 reported SBIs in 5 (12.5%) subjects (Table 2),
which is equivalent to an annualized rate of 0.05 (upper 99% CL,
0.13) infections per subject. All SBIs were acute bacterial
pneumonia and required hospitalization (thus also classified as
SAEs); no subjects discontinued the study because of SBIs. One
subject, a 6-year-old female, had a known ongoing history of
recurrent severe pneumonia; 3 days after infusion 5 in the
extension study, she developed an acute exacerbation and died
of respiratory failure 41 days later. This SAE was not related to
study medication.
Thirty-eight subjects (95.0%) had at least 1 infection during
the study, resulting in an annualized rate of infection of
3.33 infections/subject/year (95% CI 2.99, 3.70). Bronchitis0% of subjects.
ation
US study
ITT population
(N = 21)
Number of events
or days (annualized
rate per subject)
Number
(%) of
subjects
Number of events or days
(annualized rate per
subject)
5 (0.048)
[0.1252]
2 (9.5) 2 (0.06)
[0.257]
349 (3.33)
[2.993–3.703]
20 (95.2) 78 (2.38)
[1.883–2.973]
51 (0.487) 5 (23.8) 7 (0.21)
49 (0.468) 6 (28.6) 6 (0.18)
31 (0.296) 13 (61.9) 23 (0.70)
26 (0.248) 0 0
19 (0.182) 4 (19.0) 5 (0.15)
15 (0.143) 0 0
10 (0.096) 0 0
10 (0.096) 2 (9.5) 2 (0.06)
5 (0.048) 0 0
5 (0.048) 0 0
5 (0.048) 2 (9.5) 2 (0.06)
4 (0.038) 1 (4.8) 1 (0.03)
4 (0.038) 2 (9.5) 4 (0.12)
706 (6.77) 9 (49.2) 140 (4.28)
110 (1.06) 2 (9.5) 18 (0.55)
7551 (72.13) 19 (90.5) 2746 (83.87)
7) 11.98 (3.65)
study was 11,950.
165was the most frequently occurring infection (51 events),
followed by upper respiratory tract infection (49 events),
sinusitis (31 events), and cough (26 events). Twenty-seven
subjects (67.5%) missed work/school, totaling 706 days
(annualized rate, 6.77 days/subject). Seven subjects (17.5%)
were hospitalized due to infections, totaling 110 days (annual-
ized rate, 1.06 days/subject).
Immunoglobulin G levels were measured before each
infusion every 6 months for 42 months, with mean values
ranging from 7.5 to 8.8 g/L (Fig. 1). The mean (SD) of the
individual median IgG values was 7.97 g/L (1.17). One subject
with celiac disease had a pre-infusion IgG level b5 g/L at
several visits. Mean levels of specific antibodies against
Haemophilus influenzae B, Streptococcus pneumoniae, and
cytomegalovirus in the EU study population were stable
throughout, whereas antibody titers against measles virus
and tetanus toxin declined moderately over the course of the
study (data not shown).
3.3.2. US extension study
There were 2 reported SBIs in 2 subjects (9.5%; Table 2),
giving an annualized rate of 0.06 (upper 99% CL, 0.26) infec-
tions per subject. Both SBIs were bacterial pneumonia. No
deaths occurred.
Twenty subjects (95.2%) had at least 1 infection during the
study period, amounting to an annualized rate of infection of
2.38 infections/subject/year (95% CI 1.88, 2.97). Sinusitis was
the most frequently occurring infection (23 events), followed
by bronchitis (7 events), and upper respiratory tract infec-
tion (6 events). Nine subjects (42.9%) missed work/school
because of infection, totaling 140 days (annualized rate,
4.28 days/subject). Two subjects (9.5%) were hospitalized
because of infections, totaling 18 days (annualized rate,
0.55 days/subject).
Immunoglobulin G levels were measured before each in-
fusion every 24 weeks for 96 weeks, with mean values ranging
from 11.7 to 12.8 g/L (Fig. 1). The mean (SD) of the individual
median IgG values was 11.98 g/L (3.65). No subjects had an IgG
level b5 g/L during the study.0
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Figure 1 Mean steady-state IgG levels. Mean and standard
errors of the serum IgG concentrations measured during the EU
(closed squares) and US (open circles) extension studies. For the
sake of comparison between the EU and US studies, visits in the
EU study were converted from every 6 months to every 26 weeks
(1 month = 4.35 weeks).3.4. Safety
3.4.1. EU extension study
The majority of AEs in this study were considered mild (370
of 506 AEs, 73.1%) or moderate (125 of 506 AEs, 24.7%) in
intensity. A total of 39 subjects (97.5%) experienced at least
1 AE (Table 3). Eight subjects (20.0%) experienced AEs that
were considered treatment-related by the investigator
(Table 3). A total of 7 local injection-site reactions (abscess,
induration, nodule, pain, pruritus, and scar) were reported
in 6 subjects (15%), resulting in a rate of 0.13% per infusion;
local reactions were the only treatment-related AEs occur-
ring in ≥10% of subjects. Overall, 506 AEs were reported
among a total of 5405 infusions, resulting in an AE rate of 9.4%
per infusion. The most common event, excluding infections,
was arthralgia (Table 4), which was not considered related to
the study drug by the investigator, as it is a recognized side
effect of treatment. Excluding infections, there were 195 AEs,
resulting in an AE rate of 3.6% per infusion.
Eighteen SAEs occurring entirely within the time frame of
the extension study were reported in 14 subjects (35.0%),none of which were considered related to the study drug
(Table 3). An additional SAE began during the pivotal study
and continued into the extension study. Ten of the SAEs
were moderate and 2 were mild. Seven SAEs (in 5 subjects)
were severe in intensity (pneumonia [n = 3], septic shock
[n = 1], agranulocytosis [n = 1], diarrhea [n = 1], and dyspnea
[n = 1]). Most SAEs resolved without sequelae; 2 exceptions
included the subject with recurrent pneumonia described
above, and a subject with transient dyspnea associated with
signs of bronchiolitis obliterans and mild interstitial thickening.
No clinically relevant changes over time were observed
in vital signs or median values of hematology and serum
chemistry analytes. One subject, who had a history of ongoing
hemolytic anemia, had a positive direct Coombs' test at
screening and changes in hemoglobin, haptoglobin, and lactate
dehydrogenase levels that were considered unrelated to
treatment.3.4.2. US extension study
The majority of AEs were considered mild (87.0%) or moderate
(11.5%) in intensity, although all 21 subjects (100.0%) experi-
enced at least 1 event (Table 3). Overall, 1147 AEs were
reported among a total of 1735 infusions, resulting in an AE rate
of 66% per infusion. Themajority of events were local reactions
(Table 4). Excluding infections, there were 1068 AEs, resulting
in an AE rate of 62% per infusion. Excluding local reactions and
infections, the most common AE was oropharyngeal pain
(Table 4). The incidence of any AE per infusion was similar for
the different total body infusion rates: b35 mL/h (0.703), 35 to
50 mL/h (0.680), and N50 to 70 mL/h (0.584).
Excluding local reactions, 47.6% of subjects experienced
an AE that was considered treatment-related by the investiga-
tor. A total of 868 local reactions were reported in 19 subjects
(90.5%), resulting in a rate of 50% per infusion (868 per 1735
infusions). Nearly all local reactions (99.3%) were assessed by
subjects as “very slight” or “slight.” No subjects discontinued
from the extension study because of local reactions. None
were considered “severe” and only 6 (0.7%) were considered
“moderate.”
Table 3 Summary of subjects with adverse events and adverse event rates per infusion.
AE category EU study US study
No. (%) of
subjects
(N = 40)
No. (rate) of
events
(N = 5405)
No. (%) of
subjects
(N = 21)
No. (rate) of
events
(N = 1735)
AEs 39 (97.5) 506 (0.094) 21 (100) 1147 (0.661)
Mild AEs 39 (97.5) 370 (0.069) 21 (100) 998 (0.575)
Moderate AEs 25 (62.5) 125 (0.023) 18 (85.7) 132 (0.076)
At least possibly related AEs 8 (20.0) 14 (0.003) 21 (100) 909 (0.524)
SAEs 14 (35.0) 18 (0.003) 4 (19.0) 5 (0.003)
At least possibly related SAEs 0 0 0 0
Treatment-related AEs leading to discontinuation 0 0 0 0
AEs leading to death 1 (2.5) 1 (0.0002) 0 0
AE = adverse event; SAE = serious adverse event.
166 S. Jolles et al.Five SAEs were reported in 4 subjects (19.0%), none of
which were considered treatment-related. These SAEs were
cellulitis (n = 1), pneumonia (n = 1), thyroid cancer (n = 1; 2
events, 1 of which started during the pivotal study, and the
second resulted in discontinuation from the extension study),
and diarrhea (n = 1). The thyroid cancer and diarrhea were
considered severe, whereas the cellulitis and pneumonia were
moderate in intensity. All SAEs resolved without sequelae,
except for the thyroid cancer. No deaths occurred during the
study.
No clinically relevant changes over time were observed in
vital signs ormedian values of hematology and serum chemistry
analytes. Seven subjects had positive direct Coombs' test
results during the extension study, but none were assessed
as clinically significant, and there were no indications of
hemolysis in any subjects. Two of the 7 subjects also had
positive Coombs' tests before the first Hizentra administra-
tion in the pivotal trial.
3.4.3. Rates of bronchopulmonary AEs
In the EU extension study, 79 bronchopulmonary AEs were
reported during the 38,208 study days, resulting in an expo-
sure adjusted rate of 0.0021. In the US extension study, 11
bronchopulmonary AEs were reported during the 11,950
study days, resulting in an exposure adjusted rate of 0.0009.
The exposure-adjusted rate of bronchopulmonary AEs was
statistically significantly higher in the EU extension study
than in the US extension study (ratio: 2.25, 95% CI 1.21, 4.18)
as determined in a post hoc analysis.
4. Discussion
The extension studies presented here support the conclusion
that long-term repeated self-administration of Hizentra is
effective and safe, with up to 3 years of observation in
subjects with PIDD. These are the first published reports of
efficacy and safety from an extension study of any SCIG
product. Evidence of long-term efficacy and safety is im-
portant for all Ig products used to treat PIDD. Robust
protection from infections is important to avoid long-term
complications, as well as leading a full and active life.
Long-term tolerability is of particular concern to those with
chronic diseases such as PIDD, as treatment is expected to
extend throughout a patient's lifetime. Serum IgG levelsremained generally stable throughout each of these 2
extension studies, indicating that long-term, weekly subcu-
taneous administration of Hizentra maintains IgG at levels
sufficient to prevent most SBIs [16].
The ability to capture information on SBIs was not unex-
pected within the time frame of these extension studies, as
patients who receive adequate IgG therapy (with serum IgG
levels well within the normal range) may still occasionally
experience serious infections because of chronic preexisting
conditions such as chronic lung disease, particularly bronchi-
ectasis [17,18]. The observed upper 1-sided 99% confidence
limits of annualized SBI rates in both extension studies were
well below the accepted US FDA and European Medicines
Agency threshold of 1.0 [14,19].
The combined pivotal and extension studies demonstrate
the sustained activity of Hizentra in limiting the number of
SBIs experienced by patients with PIDD. However, because
SBIs are a relatively rare occurrence in clinical trials of SCIG
therapy, the use of this outcome as a measure of treatment
efficacy may not be fully reflective of the efficacy of SCIG
[9–12]. Potentially useful outcomes for future study may
include the rate of total infections, or the rate of specific, or
types, of infections (e.g., sinopulmonary infections). The
rate of any infection was slightly higher in the EU extension
study (3.33 infections/subject/year) compared with the US
extension study (2.38 infections/subject/year), but was
lower than in the EU pivotal study (5.18 infections/sub-
ject/year). The reason for this difference in infection rates
between the pivotal and extension studies may simply be
that the longer observation period in the extension studies
(including seasonal periods of low and high infection rates)
permitted a more precise assessment, as the EU pivotal
study was less than 1 year and required extrapolation to
determine the annualized rate. Furthermore, the longer
duration of the extension studies may have allowed the
disease to stabilize in some subjects, or the pivotal study
may have had a more rigorous detection process. Differences
in infection rates between the 2 extension studies may be
due to differences in the patient population. For example,
the greater percentage of children in the EU extension study
(37.5%) compared with the US extension study (4.8%), and
differences in the proportion of subjects with CVID versus
XLA, may be relevant to understanding the difference in
infection rates. Another contributing factor may have been
the difference in Hizentra doses and corresponding IgG
167levels in the 2 extension studies. Although subjects in both
extension studies began at the last dose of the corresponding
pivotal study, the average dose conversion factors when
transitioning from IVIG to SCIG in the pivotal study were 1:1
in the European Union [9] and 1:1.53 in the United States
[10]. Thus, Hizentra doses were, in general, higher in the US
extension study and therefore explain the higher steady-
state serum IgG levels observed in the US study. Higher
serum IgG concentrations during IVIG therapy have been
associated with lower rates of infections [20,21], a finding
which is corroborated by these 2 extension studies. However,
despite the differences in IgG levels in the studies, the rate of
infections converged toward that observed in the US pivotal
study. Given the key impact of primary antibody deficiency on
sinopulmonary infections, a post hoc analysis of the exposure-
adjusted rate of bronchopulmonary AEs was performed andwas
found to be statistically significantly higher in the EU extension
study than in the US extension study (ratio: 2.25, 95% CI 1.21,
4.18), suggesting a possible clinical benefit of higher IgG levels.
Although the rate of local site reactions was higher in the
US study than in the EU study, nearly all injection-site
reactions were assessed by the subject as slight or very slight
and did not lead to treatment discontinuation. No single set
of terms, grading scales, or mandatory evaluation time
points have been established for consistent use across studies
of SCIG, which points out a significant problemwith definitions
of AEs for studies of SCIG administration. The local site reac-
tions experienced by the majority of subjects in the extension
studies described here were expected physiological results of
simply injecting fluid into the subcutaneous tissue. Therefore,
differences between the rates of local site reactions in the
two studies may, in part, be explained by methodological
differences in the definition of a “reaction,” in particular by
the timing of mandatory assessment, and by the scales or
terminology employed. The results presented here reiterate
that local site reaction rates cannot be compared between
studies unless the methods for defining local site reactions are
fully described and are exactly the same. Local site reactions
following administration of SCIG are typically transient and
resolve within 24–72 h [10,22,23]. Infusion technique, siteTable 4 Most common adverse events, excluding infections (exp
Adverse event EU study
No. (%) of subjects
(N = 40)
No. (rate) o
(N = 5405)
Any adverse event 39 (97.5) 506 (0.094)
Local reactions a 6 (15.0) 7 (0.001)
Arthralgia 6 (15.0) 7 (0.001)
Abdominal pain upper 4 (10.0) 9 (0.002)
Abdominal pain 0 0
Diarrhea 4 (10.0) 6 (0.001)
Pyrexia 4 (10.0) 6 (0.001)
Back pain 3 (7.5) 3 (0.001)
Headache 2 (5.0) 6 (0.001)
Fatigue 1 (2.5) 1 (0.0002)
Oropharyngeal pain 1 (2.5) 2 (0.0004)
Anxiety 0 0
Nausea 0 0
a A group of preferred terms in the system organ class of “General dlocation, needle length, site volume, and flow rate can be
adjusted to maximize tolerability [24,25]. Because Hizentra
is formulated with L-proline, the viscosity of this product
(14.7 mPa∙s) is similar to that of the 16% Ig product
(Vivaglobin®; 14.4 mPa∙s) [26]. In addition, osmolality is
not expected to be a causative factor in the occurrence of
local site reactions [27]. For these reasons, real-world local
site reactions that are troublesome or need special manage-
ment may be expected to occur at lower rates than were seen
in some studies.
In addition to the safety and efficacy data presented
here, health-related quality of life (HRQoL) and treatment
satisfaction for the US extension study were reported
by Jones et al. [28]. High HRQoL levels were maintained
throughout the study as measured by a number of standard
and disease-specific questionnaires. All but 1 domain in the
Short-Form 36 questionnaire were within US norms; General
Health was lower than the average norm. For most visits,
subjects scored at or within US norms in the EuroQol 5D
index score. Subjects also indicated a high degree of treat-
ment satisfaction using the Treatment Satisfaction Question-
naire for Medication Short Form and a specific questionnaire
for IgG therapy. Together, these data indicate that extended
use of Hizentra is efficacious, well tolerated and helps
patients maintain a high quality of life.
Potential limitations of these extension studies may
include a self-selection bias of subjects who enrolled in the
extension studies; patients who were doing well might have
been more likely to commit to a longer observation period.
The possibility that the occurrence of AEs during the pivotal
studies may have, in part, determined a subject's willingness
to volunteer for the extension study was examined in a post
hoc analysis of safety data from the US pivotal study. This
analysis indicated that there was no statistically significant
difference in AE rates between those who discontinued after
completion of the pivotal study and those who continued
into the extension study. This suggests that an individual's
decision to participate in the extension study was influenced
by factors other than AE rates. Additional limitations
included the lack of a testable hypothesis and the limitederienced by ≥10% of subjects).
US study
f events No. (%) of subjects
(N = 21)
No. (rate) of events
(N = 1735)
21 (100) 1147 (0.661)
19 (90.5) 868 (0.5)
5 (23.8) 5 (0.003)
2 (9.5) 6 (0.003)
3 (14.3) 4 (0.002)
3 (14.3) 4 (0.002)
2 (9.5) 2 (0.001)
3 (14.3) 10 (0.006)
3 (14.3) 10 (0.006)
5 (23.8) 33 (0.019)
6 (28.6) 12 (0.007)
3 (14.3) 3 (0.002)
4 (19.0) 4 (0.002)
isorders and administration site conditions.”
168 S. Jolles et al.number of subjects available for subgroup analyses. Al-
though the number of subjects was not large, the combined
number of total infusions (7140) was the most administered
and assessed in any clinical trial of SCIG to date. Additional
strengths of the study were the age range of the subjects
and the wide geographic area encompassed.
In conclusion, the EU and US extension studies represent
the longest clinical observation of any SCIG product and
demonstrate the prolonged efficacy, safety, and tolerability
of Hizentra in the treatment of PIDD.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.clim.2013.10.008.
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